OBJECTIVE: To evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs. DESIGN: Retrospective case series. ANIMALS: 58 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each). PROCEDURES: Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors. RESULTS: Vinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days). CONCLUSIONS AND CLINICAL RELEVANCE: Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.
OBJECTIVE: To evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs. DESIGN: Retrospective case series. ANIMALS: 58 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each). PROCEDURES: Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors. RESULTS:Vinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days). CONCLUSIONS AND CLINICAL RELEVANCE: Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.
Authors: Katherine A Skorupski; Craig A Clifford; Melissa C Paoloni; Ana Lara-Garcia; Lisa Barber; Michael S Kent; Amy K LeBlanc; Aarti Sabhlok; Elizabeth A Mauldin; Frances S Shofer; C Guillermo Couto; Karin U Sørenmo Journal: J Vet Intern Med Date: 2007 Jan-Feb Impact factor: 3.333
Authors: Hannah Able; Amber Wolf-Ringwall; Aaron Rendahl; Christopher P Ober; Davis M Seelig; Chris T Wilke; Jessica Lawrence Journal: PLoS One Date: 2021-08-17 Impact factor: 3.240
Authors: Sita S Withers; Daniel York; Eric Johnson; Sami Al-Nadaf; Katherine A Skorupski; Carlos O Rodriguez; Jenna H Burton; Teri Guerrero; Kriste Sein; Luke Wittenburg; Robert B Rebhun Journal: Vet Comp Oncol Date: 2018-08-08 Impact factor: 2.613